Jeff Yass’s AC Immune ACIU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$166K Buy
69,900
+44,300
+173% +$122K ﹤0.01% 12120
2026
Q1
$70.4K Buy
+25,600
New +$79.5K ﹤0.01% 12508
2024
Q4
Sell
-12,300
Closed -$46.5K 12074
2024
Q3
$46.5K Buy
+12,300
New +$42.9K ﹤0.01% 11410
2024
Q2
Sell
-14,200
Closed -$42K 11921
2024
Q1
$42K Sell
14,200
-30,900
-69% -$111K ﹤0.01% 11623
2023
Q4
$226K Sell
45,100
-11,500
-20% -$37K ﹤0.01% 10429
2023
Q3
$161K Buy
56,600
+37,800
+201% +$115K ﹤0.01% 10466
2023
Q2
$55.6K Buy
+18,800
New +$41K ﹤0.01% 11293
2022
Q4
Sell
-15,200
Closed -$48K 12260
2022
Q3
$48K Sell
15,200
-5,200
-25% -$16.4K ﹤0.01% 12227
2022
Q2
$74K Sell
20,400
-89,000
-81% -$304K ﹤0.01% 11726
2022
Q1
$438K Buy
109,400
+37,800
+53% +$164K ﹤0.01% 9311
2021
Q4
$354K Sell
71,600
-34,900
-33% -$203K ﹤0.01% 10083
2021
Q3
$715K Sell
106,500
-44,900
-30% -$321K ﹤0.01% 8448
2021
Q2
$1.2M Sell
151,400
-107,900
-42% -$746K ﹤0.01% 7246
2021
Q1
$1.97M Buy
259,300
+143,900
+125% +$1.03M ﹤0.01% 5957
2020
Q4
$597K Sell
115,400
-21,200
-16% -$108K ﹤0.01% 7897
2020
Q3
$667K Buy
+136,600
New +$980K ﹤0.01% 7064

Other funds holding ACIU

Jeff Yass's ACIU Position: Q2 2026 in Review

Jeff Yass reduced its AC Immune (ACIU) stake by 40% in Q2 2026, selling an estimated $98.9K and leaving 53,369 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #12317.

Jeff Yass first reported a position in ACIU in Q2 2020 and has held it in 15 quarters since. The position peaked at $686K in Q4 2020. 43 funds tracked by Wall St. Rank hold ACIU as of Q2 2026.

  • Jeff Yass held 53,369 shares of AC Immune worth $127K as of Q2 2026.
  • Jeff Yass sold 35,893 AC Immune shares in Q2 2026, an estimated $98.9K.
  • AC Immune made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12317 holding.
  • Jeff Yass first reported a position in AC Immune in Q2 2020 and has held it in 15 quarters since.
  • Jeff Yass's AC Immune position peaked at $686K in Q4 2020.
  • 43 funds tracked by Wall St. Rank held AC Immune as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.